
    
      Study Population:The study population will consist of consenting patients who are on
      neuroprotectant injection for the treatment of acute IS during hospitalization. Hospitals may
      contribute differing numbers of patients to the total sample size. Primary analyses will be
      conducted on the total sample size only.

      Assessment of Outcomes:The outcome measures in this study include effectiveness, safety and
      cost measures.
    
  